

## Electronic Acknowledgement Receipt

<b>EFS ID:</b>	1010631
<b>Application Number:</b>	10538687
<b>Confirmation Number:</b>	3645
<b>Title of Invention:</b>	Cytotoxins and diagnostic imaging agents comprising hsp90 ligands
<b>First Named Inventor:</b>	Adeela KAMAL
<b>Customer Number:</b>	21971
<b>Filer:</b>	Jeffrey W. Guise./Ann Lygas/Samir Elamrani
<b>Filer Authorized By:</b>	Jeffrey W. Guise.
<b>Attorney Docket Number:</b>	23983-716.832
<b>Receipt Date:</b>	22-MAR-2006
<b>Filing Date:</b>	
<b>Time Stamp:</b>	10:18:20
<b>Application Type:</b>	U.S. National Stage under 35 USC 371
<b>International Application Number:</b>	

### Payment information:

Submitted with Payment	no
------------------------	----

### File Listing:

Document Number	Document Description	File Name	File Size(Bytes)	Multi Part	Pages
1	Information Disclosure Statement (IDS) Filed	23983-716-832IDS.pdf	534098	no	10

<b>Warnings:</b>					
<b>Information:</b>					
This is not an USPTO supplied IDS fillable form					
2	NPL Documents	Finehart.pdf	4805287	no	78
<b>Warnings:</b>					
<b>Information:</b>					
3	NPL Documents	Sambrook.pdf	1359525	no	30
<b>Warnings:</b>					
<b>Information:</b>					
4	NPL Documents	Saudek.pdf	695799	no	6
<b>Warnings:</b>					
<b>Information:</b>					
5	NPL Documents	Scheibel1.pdf	125990	no	6
<b>Warnings:</b>					
<b>Information:</b>					
6	NPL Documents	Schulte2.pdf	2472049	no	4
<b>Warnings:</b>					
<b>Information:</b>					
7	NPL Documents	Schulte.pdf	886882	no	5
<b>Warnings:</b>					
<b>Information:</b>					
8	NPL Documents	Sefton.pdf	2448330	no	21
<b>Warnings:</b>					
<b>Information:</b>					
9	NPL Documents	Segnitz.pdf	417736	no	8
<b>Warnings:</b>					
<b>Information:</b>					

10	NPL Documents	SeppLorenzo.pdf	952856	no	8
<b>Warnings:</b>					
<b>Information:</b>					
11	NPL Documents	Smith.pdf	525724	no	9
<b>Warnings:</b>					
<b>Information:</b>					
12	NPL Documents	Stebbin.pdf	3366930	no	12
<b>Warnings:</b>					
<b>Information:</b>					
13	NPL Documents	Stepanova.pdf	1120511	no	13
<b>Warnings:</b>					
<b>Information:</b>					
14	NPL Documents	Treat.pdf	460758	no	7
<b>Warnings:</b>					
<b>Information:</b>					
15	NPL Documents	Vasilevskaya.pdf	612997	no	6
<b>Warnings:</b>					
<b>Information:</b>					
16	NPL Documents	Voges.pdf	477942	no	11
<b>Warnings:</b>					
<b>Information:</b>					
17	NPL Documents	Whitesell.pdf	1439502	no	5
<b>Warnings:</b>					
<b>Information:</b>					
18	NPL Documents	Zimney.pdf	121743	no	7
<b>Warnings:</b>					
<b>Information:</b>					

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

**New Applications Under 35 U.S.C. 111**

If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.

**National Stage of an International Application under 35 U.S.C. 371**

If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.